Cocrystal Pharma: Board & Executive Compensation Changes
Ticker: COCP · Form: 8-K · Filed: Apr 8, 2025 · CIK: 1412486
| Field | Detail |
|---|---|
| Company | Cocrystal Pharma, INC. (COCP) |
| Form Type | 8-K |
| Filed Date | Apr 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-changes
TL;DR
Cocrystal Pharma shakes up board and exec pay - new era begins?
AI Summary
Cocrystal Pharma, Inc. announced on April 2, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and the election of new directors, alongside adjustments to compensatory arrangements for key personnel. This report also includes financial statements and exhibits relevant to these corporate governance and compensation updates.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, leadership stability, and future financial performance.
Risk Assessment
Risk Level: medium — Changes in board and executive compensation can indicate internal shifts that may impact future performance and strategy.
Key Players & Entities
- Cocrystal Pharma, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- April 2, 2025 (date) — Earliest event reported
FAQ
What specific roles have seen departures or appointments?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers', suggesting shifts in key leadership positions.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing occurred on April 2, 2025.
What is the primary business of Cocrystal Pharma, Inc. according to the filing?
Cocrystal Pharma, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
What state is Cocrystal Pharma, Inc. incorporated in?
Cocrystal Pharma, Inc. is incorporated in Delaware.
What other items are included in this 8-K filing besides director and officer changes?
This filing also includes 'Financial Statements and Exhibits'.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 8, 2025 regarding Cocrystal Pharma, Inc. (COCP).